Biotechnology firm Capricor Therapeutics [[1]] announced a secondary stock offering today, seeking to leverage a recent surge in share price driven by positive data in its pursuit of a disease-modifying therapy for Duchenne muscular dystrophy. The company, which focuses on cell adn exosome-based therapeutics [[2]], hopes to bolster its funding for ongoing clinical trials and potential commercial launch of its lead investigational product, deramiocel [[3]]. The offering comes amid market attention fueled by both analyst optimism and, notably, commentary from controversial investor Martin Shkreli.
Capricor Therapeutics Launches Stock Offering Following Share Price Surge
Capricor Therapeutics announced a stock offering on June 13, 2024, capitalizing on a recent significant increase in its share price. The move comes as investors react positively to promising clinical trial data and potential regulatory advancements for the company’s cell therapy programs.
The company is aiming for U.S. approval of its cell therapy for Duchenne muscular dystrophy, following successful results from a key study. This positive development has fueled investor optimism, driving up the stock’s value and creating an opportunity for Capricor to raise additional capital.
Shares of Capricor have experienced substantial volatility recently, with notable activity linked to comments from Martin Shkreli, also known as “Pharma Bro.” Shkreli, who previously held a short position in the stock, publicly discussed his views on the company’s prospects.
B.Riley has reaffirmed its ‘buy’ rating for Capricor Therapeutics following the release of positive Phase 3 data. The firm’s continued confidence in the company’s pipeline underscores the potential of its therapies to address significant unmet medical needs.
Capricor’s stock was highlighted as one of the top-performing stocks on June 13, 2024, according to XTB.com. The company’s recent gains reflect broader market trends and investor appetite for innovative biotechnology firms.
The stock offering will allow Capricor to fund ongoing research and development efforts, as well as prepare for potential commercialization of its therapies. The company did not disclose the size or terms of the offering, but further details are expected to be released in a subsequent filing.
